Abeona Therapeutics to launch gene therapy with $25M in fundraising

(Nasdaq: ABEO), a clinical-stage biopharmaceutical firm based in Cleveland, announced it has raised $25 million from “select existing investors” to help launch and commercialize its EB-101 cell therapy.

The offering was led by Nantahala Capital Management LLC. It included participation by Adage Capital Partners LP and two other existing institutional investors that Abeona did not identify. The offering will close on or…